Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Melanoma: Ipilimumab was approved by US FDA in March 2011 to treat patients with late-stage melanoma that has spread or cannot be removed by surgery. It was later approved by the US FDA on October 28, 2015 for stage 3 patients as adjuvant therapy. On February 1, 2012, Health Canada approved ipilimumab for "treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease." Ipilimumab was approved in the European Union (EU), for second line treatment of metastatic melanoma in November 2012. Renal Cell Carcinoma: On April 16, 2018, the FDA approved for advanced renal cell carcinoma the combination therapy Opdivo and Yervoy, both owned by Bristol-Myers Squibb.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Ipilimumab brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Ipilimumab tablets cost price in India.
The order for Ipilimumab will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Ipilimumab tablets, for oral use.
Injection: 50 mg/10 mL (5 mg/mL)
• Injection: 200 mg/40 mL (5 mg/mL)
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Ipilimumab on prescription and Import License in Patient's Name only.
For overseas patients, Ipilimumab can be made available in Send your enquiry to find Ipilimumab in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
Nivolumab/Ipilimumab Shows More Promising Results in Patients with Melanoma For More Details
A Look Back at FDA News from November 2019